Senescence in Chronic Kidney Disease

Prior treatment

• Concomitant glomerulonephritis,
• Solid organ transplantation,
• Active immunosuppression therapy,
• Tyrosine kinase inhibitor therapy
• Inability to tolerate oral medications
• Subjects on strong inhibitors of CYP3A4.
• Subjects on antiplatelet agents ((Clopidogrel (Plavix); Dipyridamole + Asprin (Aggrenox); Ticagrelor (Brilinta); Prasugrel (Effient); Ticlopidine (Ticlid) or Other) who are unable or unwilling to reduce or hold therapy prior to and during the 3-day drug dosing. Subjects may continue their previous regimen on day 4.
• Subjects taking H2-antagonists or proton pump inhibitors and unwilling to discontinue therapy 1 week prior and 2 weeks following enrollment.

Other illness

• Nephrotic syndrome,
• Autosomal dominant or recessive polycystic kidney disease,
• Known renovascular disease,
• History of active substance abuse (including alcohol) within the past 2 years,
• Human immunodeficiency virus infection
• Active hepatitis B or C infection
• Known hypersensitivity or allergy to dasatinib or quercetin
• New invasive cancer except non-melanoma skin cancers
• Invasive fungal or viral infection
• Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
• Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within 10 days
• Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.

Lab values

• Hemoglobin A1c≥10% at screening,
• Total bilirubin\>2x upper limit of normal
• Corrected QT interval (QTc)\>450 msec

Other

• Pregnancy,
• Current alcohol abuse (\>3 alcoholic beverages/day or \>21 per week),
• Body weight \>150 kg or body mass index\>50
• Inability to give informed consent
• Uncontrolled systemic lupus erythematosus
• Uncontrolled pleural/pericardial effusions or ascites
• Subjects on therapeutic doses of anticoagulants (Warfarin (Coumadin);Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa) or Other).

• Age 40-80 years
• Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2
• Diabetes mellitus and taking diabetes medications